Document Detail

Platelet-leukocyte interactions link inflammatory and thromboembolic events in ischemic stroke.
MedLine Citation:
PMID:  20955420     Owner:  NLM     Status:  MEDLINE    
Stroke is a common and often fatal event, and, in survivors, it is accompanied by a high risk of recurrence. Ischemic stroke is associated with abnormal platelet activity and thrombus formation. In addition to their roles in the development of acute thrombi, platelets serve as a bridge for leukocytes within the vasculature. Myeloid leukocytes are critical mediators of atherosclerosis and atherothrombosis. Interactions between platelets and leukocytes foster an inflammatory and thrombotic milieu that influences lesion progression, facilitates plaque rupture, and triggers thrombus formation and embolization. Accordingly, antiplatelet agents, including aspirin, dipyridamole, and clopidogrel, are recommended therapies for most patients with a history of stroke. In addition to mitigating thrombosis, antiplatelet drugs have direct and indirect effects on inflammation, which may translate to enhanced clinical efficacy.
Zechariah G Franks; Robert A Campbell; Andrew S Weyrich; Matthew T Rondina
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Annals of the New York Academy of Sciences     Volume:  1207     ISSN:  1749-6632     ISO Abbreviation:  Ann. N. Y. Acad. Sci.     Publication Date:  2010 Oct 
Date Detail:
Created Date:  2010-10-19     Completed Date:  2010-11-09     Revised Date:  2014-09-08    
Medline Journal Info:
Nlm Unique ID:  7506858     Medline TA:  Ann N Y Acad Sci     Country:  United States    
Other Details:
Languages:  eng     Pagination:  11-7     Citation Subset:  IM    
Copyright Information:
© 2010 New York Academy of Sciences.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Platelets / physiology
Brain Ischemia / blood,  drug therapy
Inflammation / blood,  drug therapy
Leukocytes / physiology
Platelet Aggregation Inhibitors / therapeutic use
Risk Factors
Stroke / blood*,  drug therapy
Thromboembolism / blood*,  drug therapy
Grant Support
1K23HL092161-01/HL/NHLBI NIH HHS; 5T32DK007115-35/DK/NIDDK NIH HHS; K23 HL092161/HL/NHLBI NIH HHS; K23 HL092161-02/HL/NHLBI NIH HHS
Reg. No./Substance:
0/Platelet Aggregation Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Innate inflammation as the common pathway of risk factors leading to TIAs and stroke.
Next Document:  The challenge of mixed cerebrovascular disease.